Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05976490 · ClinicalTrials.gov registry record · NA

NeuroPathways Intervention for Brain Tumor Patients

A NA study of Glioma and Coping Skills, sponsored by Massachusetts General Hospital.

Recruiting
Registry status
NA
Development phase
50
Enrollment target
1
Study location

NCT05976490: Recruiting NA study of Glioma and Coping Skills, sponsored by Massachusetts General Hospital.

NCT05976490 is a NA study of Glioma and Coping Skills that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 50 participants, below the 209-participant average among 87 other Glioma trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05976490, a NA study of Glioma and Coping Skills, is actively recruiting participants, sponsored by Massachusetts General Hospital.

RECRUITING
Registry status
NA
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

This goal of this study is to test an information and support intervention for patients with malignant (or "high-grade") brain tumors. This study was developed to help patients cope after a brain tumor diagnosis. The main question this study aims to answer is whether this intervention (which includes access to an information guide and one-on-one coaching sessions) is feasible (i.e., possible to carry out) and acceptable (i.e., considered helpful) to patients. Participants will be asked to take part in the coaching sessions, use the guide as desired, and complete a small group of short surveys at three different points in time; some participants will be asked to share feedback via exit interviews.

Primary Outcome

The investigators will assess feasibility by examining the percentage of eligible patients who agree to enroll in the study and the percentage of enrolled patients who participate in all four intervention sessions. The intervention will be deemed feasible if at least 60% of eligible patients enroll in the study and if at least 60% of enrolled patients complete all four sessions.

Interventions

  • OTHER Usual supportive care
  • BEHAVIORAL Information and Support Intervention

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital Cancer Center - Boston

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2023-11-07
Est. Completion 2027-04-10
Phase NA
Massachusetts General Hospital

2,032 total trials

What NCT05976490 shows while recruiting

NCT05976490 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 209-participant average among 87 other Glioma trials with a reported enrollment target (76% lower).

The record links to 3 conditions, with Glioma appearing as the primary indexed condition, and to 2 interventions - of which Usual supportive care is the first listed.

NCT05976490 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05976490 about?

NCT05976490 is a clinical study titled "NeuroPathways Intervention for Brain Tumor Patients". This goal of this study is to test an information and support intervention for patients with malignant (or "high-grade") brain tumors. This study was developed to help patients cope after a brain tumor diagnosis. The main question this study aims to answer is whether this intervention (which include...

What is the current status of trial NCT05976490?

This trial is currently recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2023-11-07. Estimated completion is 2027-04-10.

What conditions does trial NCT05976490 study?

This clinical trial studies the following conditions: Glioma, Coping Skills, Malignant Brain Tumor.

What interventions are being tested in trial NCT05976490?

The interventions under investigation include: Usual supportive care (OTHER), Information and Support Intervention (BEHAVIORAL).

Who is sponsoring clinical trial NCT05976490?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05976490 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Glioma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05976490's enrollment target sits among peer trials

50 37th of 87 higher than 48 of 87 other Glioma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Glioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05976490, the US trial registry maintained by the National Library of Medicine. NCT05976490 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.